The surprising failure of AstraZeneca and Ionis in a key phase 3 trial of Wainua in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) has sent the companies' shares tumbling, while ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results